Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
The primary end point was amended from overall survival (OS) to progression-free survival (PFS).
首要观察终点从总生存期(OS)改为无进展生存期(PFS)。
应用推荐